White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
Members of Congress say that won’t work.
Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
After a “humble” start at NCI, von Eschenbach set unachievable goal.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - Letai takes a swipe at “ill-informed commentators,” as he lays out his scientific vision for NCI
“To my knowledge, 100% of grants that clear my desk get funded” - Senthil K. Muthuswamy named director of NCI’s Center for Cancer Research
